Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PREFRIN-A vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PREFRIN-A contains phenylephrine, an alpha-1 adrenergic receptor agonist, and acetaminophen, a centrally acting analgesic and antipyretic. Phenylephrine causes vasoconstriction in nasal mucosa, reducing congestion. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Temporary relief of nasal congestion,Fever reduction,Mild to moderate pain relief
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Terminal elimination half-life: 2-4 hours in adults; 6-12 hours in neonates and infants due to immature hepatic metabolism.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Phenylephrine undergoes extensive first-pass metabolism by monoamine oxidase (MAO) in the liver and gut; acetaminophen is primarily metabolized by glucuronidation and sulfation, with minor CYP2E1 oxidation to a hepatotoxic metabolite NAPQI.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% as metabolites.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Phenylephrine: 50-60% bound to albumin and alpha-1-acid glycoprotein; Antazoline: ~20% bound to albumin.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Phenylephrine: Vd ~0.5 L/kg (distributes primarily into extracellular fluid); Antazoline: Vd ~2 L/kg (extensive tissue distribution).
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Ocular: <1% systemic bioavailability after topical administration; intranasal: 10-20% systemic bioavailability; oral: 2-5% due to first-pass metabolism.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
No dosage adjustment required for renal impairment.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No dosage adjustment required for hepatic impairment.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Children ≥6 years: 1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily. Children <6 years: not recommended.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Use with caution due to increased risk of systemic absorption and adverse effects; consider lowest effective dose and frequency.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
None.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Avoid use in patients with hypertension, hyperthyroidism, diabetes, or cardiovascular disease. Risk of hepatotoxicity with acetaminophen overdose. Do not exceed recommended dose. Avoid concurrent use with MAO inhibitors.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypersensitivity to phenylephrine, acetaminophen, or any excipients. Severe hypertension or coronary artery disease. Concomitant use or within 14 days of MAO inhibitors.
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Avoid alcohol and products containing caffeine or other stimulants as they may increase the risk of cardiovascular adverse effects. No specific food restrictions beyond maintaining hydration.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Phenylephrine (sympathomimetic) and pyrilamine (antihistamine) combination. No adequate well-controlled studies in pregnant women. Phenylephrine may cause uterine vasoconstriction and reduced placental perfusion; risk of fetal hypoxia in third trimester. Pyrilamine: Class B in pregnancy; animal studies show no fetal harm. Avoid in first trimester due to theoretical risk of vasoconstriction. Use only if benefit outweighs risk.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Phenylephrine: minimal excretion in breast milk; M/P ratio unknown. Pyrilamine: not known if excreted. Antihistamines may cause drowsiness or irritability in infant. Avoid if possible due to lack of safety data. Consider alternative with more data.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No specific dose adjustment recommendations due to lack of pharmacokinetic studies in pregnancy. Use lowest effective dose for shortest duration. Consider alternative agents if possible.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Prefrin-A combines phenylephrine (alpha-1 agonist vasoconstrictor) with pyrilamine (first-generation antihistamine). Use with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes, or narrow-angle glaucoma. Avoid in patients taking MAO inhibitors or within 14 days of discontinuation. Rebound congestion can occur with prolonged use (>3 days). Monitor for CNS depression or paradoxical excitation in children.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Use exactly as directed; do not use for more than 3 days to avoid rebound congestion.,Avoid driving or operating machinery if drowsiness occurs, especially when combined with alcohol or other CNS depressants.,Do not use if you have high blood pressure, heart disease, thyroid problems, diabetes, or glaucoma unless directed by a doctor.,Discontinue use and consult a doctor if symptoms persist or worsen, or if you experience severe dizziness, headache, or irregular heartbeat.,Store at room temperature away from moisture and heat. Keep out of reach of children.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
No interactions on record
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PREFRIN-A vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
PREFRIN-A is a Ophthalmic Decongestant/Antihistamine Combination that works by PREFRIN-A contains phenylephrine, an alpha-1 adrenergic receptor agonist, and acetaminophen, a centrally acting analgesic and antipyretic. Phenylephrine causes vasoconstriction in nasal mucosa, reducing congestion. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PREFRIN-A and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PREFRIN-A is: 1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PREFRIN-A and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PREFRIN-A is classified as Category C. Phenylephrine (sympathomimetic) and pyrilamine (antihistamine) combination. No adequate well-controlled studies in pregnant women. Phenylephrine may cause uterine vasoconstriction . AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.